Karikó: the woman rejected two hundred times who lit up the world's vaccines

In 1989, in a hallway at the University of Pennsylvania, a young researcher with a Hungarian accent carried a thick stack of lab notes and knocked on the chairman's door.

Her name was Katalin Karikó. She wanted a small research grant to study something everyone at the time considered useless: putting messenger RNA into the human body, to see whether it could teach our own cells to make medicine.

The chairman listened politely and told her: this is too far-fetched, too unreliable, not worth funding.

That was only the beginning. Over the next thirty-plus years, she was turned down again and again. Grants rejected. Papers bounced. Colleagues walked past her in the hallway. In 1995 she was denied tenure, moved off the tenure track, and her salary was cut in half. She was in her early thirties; her husband worked odd jobs in America, and her daughter was still in primary school. Colleagues told her: switch topics, this line of research goes nowhere, and no one will ever care.

She did not switch.

She later recalled those years as the ones where she got used to sitting in the back row at conferences, because no one ever invited her to speak. While her lab mates went home in the evening, she stayed behind, kept feeding cells, mixing reagents, writing notes. Her collaborator Drew Weissman initially thought her idea was outlandish, until the two fell into a twenty-minute chat while waiting in line at the photocopier. That twenty minutes is what made him decide to work with her.

Together they faced a problem almost no one could solve: injecting mRNA directly into an animal triggered a violent inflammatory reaction. Animals spiked fever, went into shock, died. The mainstream scientific community wrote off the whole approach on that evidence.

But in failure after failure, Karikó and Weissman noticed a detail everyone else had missed: mRNA that had been chemically modified could fool the body's alarm system, slip quietly into cells, and avoid the violent reaction. That single, unglamorous modification became the foundation of every mRNA vaccine that followed.

They submitted the paper. Journals were not interested. In 2005, that now-landmark paper appeared in a low-impact, little-read journal, and barely anyone cited it. Another dozen years passed before a tiny biotech company was willing to turn the discovery into a drug.

Then came 2020.

A new coronavirus spread across the planet. Lockdowns, masks, empty streets. Labs everywhere raced down the same track, and the first two vaccines out of the gate were both built on the mRNA technology Karikó and Weissman had begun studying more than thirty years earlier.

That winter, hundreds of millions of people lined up to roll up a sleeve. Inside the syringe was the chemically modified strand she had validated, again and again, through the years of being laid off, rejected, written off as a dreamer.

In 2023, in her seventies, she finally received the Nobel Prize in Physiology or Medicine. Standing on the stage in Stockholm, she said: don't be afraid of rejection. Every "no" only makes you clearer about where you are going.

The most valuable discoveries in the world are rarely made in the applause. They are made outside the meeting room, beside the photocopier, in all the years when no one would let you finish your sentence — by someone who refused to leave.

After the prize, a reporter asked her: after so many rejections, didn't you ever want to quit?

She thought for a moment. "Every single day," she said. "But the next morning, I still walked into the lab."

Her daughter remembered growing up in a house full of her mother's papers and reagent bottles, with data spread across the dinner table. Her mother never preached "perseverance" at home. She simply went to work every morning, was turned down, came home, and went back the next day.

Today, mRNA technology is moving beyond vaccines into a wider world — cancer treatments, rare diseases, conditions once considered untreatable. Every new candidate entering a clinical trial traces back to that Hungarian woman who knocked on the chairman's door in 1989.

She had no slogan for changing the world. She simply, when everyone said it couldn't be done, ran one more experiment.